6:23 PM
 | 
Sep 18, 2008
 |  BC Extra  |  Clinical News

Ustekinumab v. Enbrel data

Johnson & Johnson (NYSE:JNJ) said both doses of ustekinumab were superior vs. Enbrel etanercept in treating chronic moderate to severe psoriasis in a single-blind, head-to-head Phase III trial in 903 patients. Patients received 45 or 90 mg of subcutaneous ustekinumab at weeks 0 and 4 or twice-weekly 50 mg subcutaneous Enbrel for 12 weeks.

On...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >